このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

早期アルツハイマー病の参加者におけるブンタネットタップの安全性と有効性を評価する6か月および18か月のランダム化二重研究 (DUET-AD)

2026年11月16日 更新者:Annovis Bio Inc.

早期アルツハイマー病参加者の治療におけるブンタネタップの有効性と安全性を調査する6か月および18か月の前向き無作為化プラセボ対照二重盲検二重臨床試験

The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen. The main questions it aims to answer are:

  • Does buntanetap/Posiphen improve cognition as measured by ADAS-Cog13?
  • Does buntanetap/Posiphen improve function as measured by ADCS-iADL?
  • What medical issues do participants have, if any, when taking buntanetap/Posiphen?

Researchers will compare buntanetap/Posiphen to a placebo (a look-alike substance that contains no drug) to see if buntanetap/Posiphen works to treat early Alzheimer's disease.

Participants will:

  • Take buntanetap/Posiphen or a placebo every day for 18 months
  • Visit the clinic periodically for checkups, tests, and questionnaires (screening visits, enrollment, month 1, month 3, month 6, month 9, month 12, month 15, month 18), including a volumetric MRI at month 6 and month 18
  • Complete pre- and post-clinic visit phone calls

調査の概要

状態

積極的、募集していない

条件

介入・治療

研究の種類

介入

入学 (実際)

861

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Arizona
      • Chandler、Arizona、アメリカ、85286
        • MD First Research
      • Phoenix、Arizona、アメリカ、85004
        • Xenoscience
      • Scottsdale、Arizona、アメリカ、85258
        • Clinical Endpoints
    • California
      • Anaheim、California、アメリカ、92805
        • Advanced Research Center
      • Canoga Park、California、アメリカ、91303
        • Hope Clinical Research
      • Imperial、California、アメリカ、92251
        • Sun Valley Research
      • Los Angeles、California、アメリカ、90095
        • Mary S. Easton Center for Alzheimer's Research and Care, UCLA
      • Sacramento、California、アメリカ、95816
        • UC Davis Alzheimer's Disease Research Center
      • San Marcos、California、アメリカ、92069
        • The Neuron Clinic
    • Colorado
      • Basalt、Colorado、アメリカ、81621
        • Mountain Neurological Center
      • Englewood、Colorado、アメリカ、80113
        • CenExel Rocky Mountain
    • Connecticut
      • Norwalk、Connecticut、アメリカ、06851
        • Research Center for Clinical Trials
    • Florida
      • Aventura、Florida、アメリカ、33180
        • Visionary Investigators Network
      • Boca Raton、Florida、アメリカ、33487
        • SFM Clinical Research
      • Clermont、Florida、アメリカ、34711
        • K2 Medical Research
      • Daytona Beach、Florida、アメリカ、32114
        • K2 Medical Research Daytona
      • Fort Myers、Florida、アメリカ、33912
        • Neuropsychiatric Research Center
      • Hallandale、Florida、アメリカ、33009
        • Velocity Clinical
      • Jacksonville、Florida、アメリカ、32216
        • Jacksonville Center for Clinical Research
      • Lady Lake、Florida、アメリカ、32159
        • K2 Medical Research
      • Lake Worth、Florida、アメリカ、33462
        • Headlands Research JEM
      • Lakeland、Florida、アメリカ、33803
        • Accel Research Sites Lakeland (Alcanza)
      • Maitland、Florida、アメリカ、32751
        • K2 Medical Research
      • Melbourne、Florida、アメリカ、32940
        • ClinCloud Clinical Research
      • Merritt Island、Florida、アメリカ、32952
        • Flourish Research/Merritt Island Medical Research
      • Miami、Florida、アメリカ、33137
        • Miami Jewish Health
      • Naples、Florida、アメリカ、34102
        • Aqualane Clinical Research
      • New Port Richey、Florida、アメリカ、34652
        • Suncoast Clinical Research
      • Orlando、Florida、アメリカ、32832
        • Conquest Research
      • Tampa、Florida、アメリカ、33609
        • Axiom Brain Health, LLC
      • Winter Park、Florida、アメリカ、32789
        • Conquest Research
    • Georgia
      • Decatur、Georgia、アメリカ、30030
        • Accel Neurosciences
      • Gainesville、Georgia、アメリカ、30501
        • CARE (Center for Advanced Research & Education)
    • Hawaii
      • Honolulu、Hawaii、アメリカ、96817
        • Hawaii Pacific Neuroscience
    • Illinois
      • Chicago、Illinois、アメリカ、60612
        • Rush University Medical Center
      • Chicago、Illinois、アメリカ、60611
        • Re:Cognition Chicago
      • Chicago、Illinois、アメリカ、60618
        • Charter Research Chicago
      • Chicago、Illinois、アメリカ、60640
        • Great Lakes Clinical Trials/Flourish Research
      • Springfield、Illinois、アメリカ、62702
        • Southern Illinois University
    • Indiana
      • Indianaopolis、Indiana、アメリカ、46256
        • JWM Research
    • Kansas
      • Wichita、Kansas、アメリカ、37214
        • Ascension via Christi Research
    • Louisiana
      • Metairie、Louisiana、アメリカ、70006
        • Tandem Intermediate
    • Maryland
      • Pikesville、Maryland、アメリカ、21208
        • Headlands Research Pharmasite
    • Massachusetts
      • Foxborough、Massachusetts、アメリカ、02035
        • Neurology Center of New England, PC
      • Plymouth、Massachusetts、アメリカ、02360
        • Headlands Research Easter Massachusetts
      • Russells Mills、Massachusetts、アメリカ、02747
        • Mayflower Clinical
      • Springfield、Massachusetts、アメリカ、01103
        • Elixia MA
    • Michigan
      • Farmington Hills、Michigan、アメリカ、48334
        • Quest Research Institute
    • Mississippi
      • Flowood、Mississippi、アメリカ、39232
        • Precise Research Center
    • Missouri
      • Chesterfield、Missouri、アメリカ、63005
        • Clinical Research Professionals - Headlands Research
    • Nevada
      • Las Vegas、Nevada、アメリカ、89121
        • Oasis Clinical Trials LLC
    • New Jersey
      • Toms River、New Jersey、アメリカ、08755
        • Cenexel Advanced Medical Research of New Jersey (AMRI)
      • West Long Branch、New Jersey、アメリカ、07764
        • Advanced Clinical Institute
    • New York
      • Amherst、New York、アメリカ、14226
        • Dent Neurologic Institute
      • Brooklyn、New York、アメリカ、11235
        • SPRI
      • Lake Success、New York、アメリカ、11042
        • Neurological Associates of Long Island
      • New York、New York、アメリカ、10003
        • New York Neurology Associates
      • Staten Island、New York、アメリカ、10314
        • Richmond Behavioral Associates
      • Syracuse、New York、アメリカ、13210
        • Ichor Research
    • North Carolina
      • Durham、North Carolina、アメリカ、27705
        • Duke University
      • Matthews、North Carolina、アメリカ、28105
        • AMC Research/Flourish Research
    • Ohio
      • Beavercreek、Ohio、アメリカ、45432
        • American Clinical Research Center
      • Centerville、Ohio、アメリカ、45459
        • Valley Medical Research
      • Independence、Ohio、アメリカ、44131
        • Insight Clinical Trials
    • Oregon
      • Portland、Oregon、アメリカ、97210
        • Summit Headlands
    • Pennsylvania
      • Media、Pennsylvania、アメリカ、19063
        • Suburban Research Associates
      • Plymouth Meeting、Pennsylvania、アメリカ、19462
        • K2 Keystone
    • Rhode Island
      • East Providence、Rhode Island、アメリカ、02914
        • Rhode Island Mood and Memory Research Institute
    • South Carolina
      • Summerville、South Carolina、アメリカ、29486
        • Palmetto Primary Care & Specialty Physicians
    • Tennessee
      • Cordova、Tennessee、アメリカ、38018
        • Neurology Clinic, P.C.
      • Nashville、Tennessee、アメリカ、37204
        • K2 Medical Research Nashville
    • Texas
      • Austin、Texas、アメリカ、78757
        • Senior Adults Specialty Research
      • Houston、Texas、アメリカ、77094
        • NeuroMind Clinical Trials
      • Round Rock、Texas、アメリカ、78681
        • Central Texas Neurology Associates
      • Wichita Falls、Texas、アメリカ、76309
        • Grayline Research Center
    • Vermont
      • Bennington、Vermont、アメリカ、05201
        • Memory Clinic, Inc.
    • Virginia
      • Arlington、Virginia、アメリカ、22205
        • Sana Research
      • Fairfax、Virginia、アメリカ、22031
        • Re:Cognition Fairfax

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

55年~85年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Diagnosis of AD according to the 2024 National Institute on Aging and Alzheimer's Association criteria.

  2. Male or female, aged 55 - 85 years.

  3. MMSE 20-28 at screening and baseline.

  4. CDR global score=0.5 or 1, with memory box score at least 0.5 at screening and baseline.

  5. Positive for amyloid beta as defined by plasma p-tau217 level at screening.

  6. Neuroimaging (MRI) consistent with the clinical diagnosis of AD and without findings of significant exclusionary abnormalities (see exclusion criteria # 4). A historical MRI, up to 1 year prior to screening, may be used as long as there have been no interval clinical neurologic events that may suggest a change in the MRI scan.

  7. Have a study partner who will provide written informed consent to participate, is in frequent contact with the participant (defined as at least 10 hours per week) and will accompany the participant on study visits at designated times.

  8. Female participants of childbearing potential* must have a negative urine pregnancy test at screening, must be non-lactating and must agree to use a highly effective method of contraception (i.e., a method resulting in a failure rate of less than 1% per year when used consistently and correctly) during the trial and for one month after the last dose of trial treatment, such as:

    • Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,

    • Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,

    • Intrauterine device (IUD),

    • Intrauterine hormone-releasing system (IUS),

    • Bilateral tubal occlusion,

    • Vasectomized partner (a vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the participant. If not, an additional highly effective method of contraception should be used),

    • Sexual abstinence (sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant).

      • Non-childbearing potential includes surgically sterilized or postmenopausal with no menstrual bleeding for at least one year prior to study start.
  9. Male participants must be sterile or sexually inactive or agree not to father a child during the study and one month after the last dose of study medication and must agree to use a barrier method for contraception. Female partners of male participants must adopt a highly effective method of contraception with a failure rate of less than 1% per year when used consistently and correctly such as:

    • Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,
    • Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,
    • IUD,
    • IUS,
    • Bilateral tubal occlusion.
  10. General cognition and functional performance sufficiently preserved that the subject can provide written informed consent. At re-consent, a legally authorized representative may co-sign if participants do not meet the general cognition and functional performance needed in the opinion of the investigator.

  11. No evidence of current suicidal ideation or previous suicide attempt in the past month as evaluated in the Columbia Suicide Severity Rating Scale.

  12. Stability of permitted medications for at least 4 weeks prior to screening. Refer to Concomitant Medications section for details on prohibited and permitted medications.

    • Cholinesterase inhibitors and/or memantine medication,
    • Anticonvulsant medications used for epilepsy or mood stabilization, or neuropathic pain indications, and have not had a breakthrough seizure in 3 years prior to screening
    • Mood-stabilizing psychotropic agents including, but not limited to, lithium.
  13. Adequate visual and hearing ability (physical ability to perform all the study assessments).

  14. Participants previously exposed to buntanetap can still be included in the study after a 28-day wash out period.

Exclusion Criteria:

  1. Has a history of psychiatric disorder such as schizophrenia, bipolar disorder, or major depression according to the criteria of the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM), unless they are stable on treatment or no longer need treatment. Mild depression or history of depression that is stable on treatment with selective serotonin reuptake inhibitors (SSRI), serotonin and norepinephrine reuptake inhibitors (SNRI) or other anti-depression medication (e.g. Wellbutrin) at a stable dose is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

  2. Has non-AD dementia, such as vascular dementia, Lewy body dementia, frontotemporal disease, PD dementia, B12 and thyroid deficiency caused dementia.

  3. History of a seizure disorder, if stable on medication is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

  4. Screening MRI (or historical MRI, if applicable) of the brain indicative of significant abnormality, including, but not limited to, prior hemorrhage (>5) or infarct > 1 cm3, > 3 lacunar infarcts, cerebral contusion, encephalomalacia, aneurysm, vascular malformation, subdural hematoma, hydrocephalus, space-occupying lesion (e.g., abscess or brain tumor such as meningioma unless they are documented and stable).

  5. Has a history or current evidence of long QT syndrome, Fridericia's formula corrected QT (QTcF) interval ≥ 450 ms for men and ≥ 460 ms for women ((in the absence of a bundle branch block), or torsades de pointes.

  6. Has bradycardia (<50 bpm) or tachycardia (>100 bpm) on the ECG at screening and deemed medically significant by the PI.

  7. Has uncontrolled Type-1 or Type-2 diabetes. A participant with hemoglobin subunit alpha 1c (HbA1c) levels up to 7.5% can be enrolled if the PI believes the participant's diabetes is under control.

  8. Has clinically significant renal (Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) <50 mL/min/BSA (body surface area) or hepatic impairment (alkaline phosphatase (ALP) > 2.0 ULN and/or total bilirubin > 2.0 ULN).

  9. Has any clinically significant abnormal laboratory values. Participants with liver function tests (aspartate aminotransferase (AST) or alanine aminotransferase (ALT)) greater than twice the upper limit of normal will be excluded.

  10. Is at imminent risk of self-harm, based on clinical interview and responses on the C- SSRS, or of harm to others in the opinion of the PI. Participants must be excluded if they report suicidal ideation with intent, with or without a plan or method (e.g., positive response to items 4 or 5 in assessment of suicidal ideation on the C-SSRS) in the past 2 months, or suicidal behavior in the past 6 months.

  11. Has cancer or has had a malignant tumor within the past year, except participants who underwent potentially curative therapy with no evidence of recurrence (participants with stable untreated cancer are not excluded).

  12. Alcohol / Substance use disorder, moderate to severe, in the last 5 years according to the most current version DSM.

  13. Participation in another clinical trial with an investigational agent and have taken at least one dose of study medication, unless unblinded on placebo, within 4 weeks prior to the start of screening, or five half-lives of the investigational drug, whichever is greater. The end of a previous investigational trial is the date the last dose of an investigational agent was taken.

  14. Participants with learning disability or developmental delay.

  15. Participants whom the PI deems to be otherwise ineligible.

  16. Participants with a known allergy to the investigational drug or any of its components.

    Inactive ingredients of the investigational medicinal product:

    • Silicified Microcrystalline Cellulose
    • Dibasic Calcium Phosphate Dihydrate
    • Mannitol
    • Stearic Acid
    • Hypromellosee (capsule shells structure)
    • Titanium dioxide (opacifier of the capsule shells)
  17. Participant is currently pregnant, breast-feeding, and/or lactating.

  18. Participant is currently taking strong and moderate CYP3A4 inhibitors and/or inducers. Refer to Concomitant Medications section below for details on prohibited and permitted medications.

  19. Participants with uncontrolled hypertension (systolic >160mm Hg and/or diastolic >95mm Hg) or hypotension (systolic <90mm Hg and/or diastolic <60 mm Hg) and deemed medically significant by the PI.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
プラセボコンパレーター:プラセボ

Placebo capsule by mouth once daily for 18 months

実験的:ブンタネタップ

30mg capsule by mouth once daily for 18 months

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13)
時間枠:From screening to 6-month readout, to end of treatment at 18 months.

ADAS-Cog13 includes the original ADAS-Cog11 items that assess cognitive function across the memory, language, praxis, and orientation domains and adds a number cancellation task and a delayed free recall task. Total scores range from 0-85, with higher scores indicating greater cognitive impairment.

From screening to 6-month readout, to end of treatment at 18 months.
Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Scale (ADCS-iADL)
時間枠:From screening to 6-month readout, to end of treatment at 18 months.

The Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale (ADCS-ADL) is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's study partner to assess function to the degree to which the participant can perform a variety of tasks. The questionnaire asks 6 questions of basic ADLs and 17 instrumental ADLs. The iADL are more complex tasks, including activities such as shopping, maintaining appointments, or managing one's belongings or finances. The ADCS-iADL subset is assessed with items 6a and 7-23; scores range from 0 to 59, with lower scores indicating greater impairment in function.

From screening to 6-month readout, to end of treatment at 18 months.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

便利なリンク

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年2月4日

一次修了 (推定)

2027年12月1日

研究の完了 (推定)

2028年6月1日

試験登録日

最初に提出

2024年11月26日

QC基準を満たした最初の提出物

2024年11月26日

最初の投稿 (実際)

2024年11月29日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月19日

QC基準を満たした最後の更新が送信されました

2026年11月16日

最終確認日

2026年5月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • ANVS-25001

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。